[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][=C][Branch2][Ring2][Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][C][=N][C][=N][C][=C][Ring1][=Branch1][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=N][C][Branch1][Branch1][C][O][Ring1][Branch1][Branch1][C][C][C][O][C][=C][C][=N][C][=N][N][Ring1][Branch1][C][=C][Ring1][=Branch2]"}, {"from": "gpt", "value": "The molecule is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens."}]